Open in interactive viewer → charts, metric popovers & call review

Azenta Doubled Before the Turnaround Showed Up

A new interim CEO, two gene-synthesis deals, and a +99.5% 90-day run meet a 3-5% organic growth guide.
AZTA · Earnings Call · 2026-11-11

The stock moved before the story did

Azenta’s fiscal fourth-quarter report lands in an awkward place: the operating business is still small, slow-growing and only marginally profitable, but the stock has already staged one of the more violent re-ratings in life-science tools. The shares returned +99.5% over the last 90 trading days, according to the tape, even though they remain -60.6% below the 2021 peak. That is the central tension. Management is asking investors to underwrite a turnaround; the market has already paid for a good chunk of it.

The base is not yet inspiring. Latest filed quarterly total revenue was $161M, up 12% year over year but still 38% below the 2021 high. Operating income was -$4M, and free cash flow was -$10M. The Q4 call was better: revenue of $167M, up 5% reported and 2% organic, with FY26 revenue of $622M and adjusted EBITDA of $58.3M, a 9.4% margin. But “better” here means less bad, not yet good.

Interim CEO Martin Madaus, three months into the job, framed it as stabilization: “We closed fiscal 2026 with good progress towards improving the business. The second half was significantly better than the first.” — Martin Madaus, Interim President and Chief Executive Officer · 2026-11-11 The second half was indeed better, particularly in Multiomics North America. But the prior call’s CFO had warned that “one quarter doesn't really evidence a broad-based sustained market recovery yet.” — Lawrence Lin, CFO or Head of Finance · 2026-08-05 Two quarters later, the market has decided otherwise.

The gene-synthesis pivot is real — and early

The genuinely new item is the repositioning of Multiomics around gene synthesis and AI-enabled drug discovery. Azenta announced an exclusive license to Elegen’s cell-free DNA synthesis platform and acquired SynPlexity, adding pooled, high-throughput gene libraries. Management argues these fill the “fragment” half of the synthesis market that Azenta did not address, doubling its addressable opportunity in Gene Synthesis and connecting digital designs to wet-lab validation.

AI is increasing the number and complexity of biological designs researchers can evaluate, but those digital antibody designs still need to be built, tested, and validated experimentally to move the models forward.

William Martin, Executive (likely President or similar, involved in Multiomics and GENEWIZ operations) · 2026-11-11

That is a credible strategic logic. The drug discovery workflow is moving toward more designs, more iterations and more data per dollar — a phrase Trey Martin used repeatedly — and Azenta’s existing GENEWIZ customer relationships and global salesforce give it a distribution channel the small acquired technologies lack. The data per dollar argument is also the right one for AI-era buyers: high throughput and high purity DNA are not commodity claims if they actually shorten the design-build-test cycle.

But the financial contribution is deliberately back-ended. FY27 is described as “integration, scale-up, and early commercialization.” The deals are expected to be ~100 bps dilutive to FY27 EBITDA margin and positive in the second year. The high end of revenue guidance includes “potential contributions” — not a firm number. That is not yet a growth engine; it is an option.

What management stopped saying

The more interesting signal may be what disappeared from the call. For several quarters, Azenta’s prior CEO anchored the story to the long-range plan and the Investor Day: a $6B SAM, high-single-digit growth and an 18%–20% EBITDA margin. On the August call, CFO Lawrence Lin was still explicit: “we'll certainly hit the full year -- full LRP basis and get to 18% to 20% that we've talked about.” — Lawrence Lin, CFO or Head of Finance · 2026-08-05

On this call, when an analyst asked for a temperature check on the LRP, Madaus deflected: “Our focus is really on '27 and delivering against the commitments that we laid out for this year.” — Martin Madaus, Interim President and Chief Executive Officer · 2026-11-11 That is prudent for an interim CEO, but it is also an admission that the old long-range targets are no longer the operating contract. The FY27 guide implies roughly 11.5%–12% EBITDA margin at the midpoint — a big step up from 9.4%, but nowhere near the old LRP destination.

The same narrowing shows up in the keyword trail. Sanger sequencing was a top-three company keyword in 2026Q3; it remains a headwind, but management now says it will be “much smaller” in 2027. The prior CEO had already quantified the problem: “The biggest driver in North America is, of course, related to Azenta-specific, and that is our Sanger business. I mean that is declining 17%.” — John P. Marotta, Chief Executive Officer · 2026-05-06 The decline is not new; the willingness to shrink the U.S. lab footprint around it is. Automated Stores, meanwhile, has gone from a top-ranked quality problem to a “return to modest growth” promise, with two new products launching at the end of FY27 and real impact in 2028. That is a long runway for a business the market may be discounting today.

The math of a doubled stock

Azenta has the balance sheet to be patient: $506M of cash and marketable securities, no debt, and $132M left on the buyback after repurchasing $118M of stock in FY26. Against a ~$2.1B market cap, cash is roughly a quarter of the equity value. That supports the “cheap optionality” case. But the income statement still has to do the work. Gross margin was 44.9% in the latest filed quarter, and R&D was $9M against $161M of revenue. For a company asking investors to believe in a technology-led reinvention, that is a modest innovation budget.

The FY27 EBITDA bridge is plausible: roughly 300 bps from volume and mix, 400 bps from restructuring, productivity and automation, offset by ~100 bps of dilution and continued growth investment. The restructuring is expected to save $11M annualized, with $7M from earlier actions. But the guide also assumes a return to growth in Automated Stores, a U.K. Biocentre ramp, better booking trends, and a smaller Sanger drag. Those are mostly company-controlled, which is the bull case. They are also mostly unproven for more than one quarter.

The stock’s 90-day double says the market is treating the Q4 inflection as the start of something durable. The report itself says something more modest. CFO Lawrence Lin framed the guide plainly: “For fiscal 2027, we expect total reported revenue in the range of approximately $648 million to $660 million, representing organic growth of approximately 3% to 5% year-over-year.” — Lawrence Lin, Chief Financial Officer · 2026-11-11 That is a good year for a turnaround, not a growth company’s year. If Q1 delivers only 3%–4% organic growth and negative free cash flow — as guidance implies — the rerating will need the gene-synthesis option to keep carrying it, with cash generation improving only ~25% off a low base.

Azenta is no longer a broken story, but it is not yet a proven one. The new team has a coherent plan: stabilize the core, shrink Sanger, fix Stores, and buy a position in AI-enabled gene synthesis. The risk is timing. The equity has already moved as if the plan is working; the P&L has only just started to agree.